> A new treatment for advanced and end-stage glaucoma
Primary angle glaucoma, primary angle closure glaucoma, pseudo-exfoliation, neovascular glaucoma, glaucoma associated with steroid uses, uveitis and after keratoplasty surgery(1)
> A very efficient non thermal procedure leading to a reduction in the medication regimen
Significant and persistent reduction in IOP at 9 months(1)
30 % decrease from baseline and less than 21 mmHg |
Mean number of medication(1)
|
> SubCyclo® preserves the structures of the ciliary body (no destructive effects) and improves the uveoscleral drainage
|
After treatment:
|
|
> SubCyclo® avoids the side effects of the thermal cyclophotocoagulation procedure
No serious side effects such as intraocular inflammation after treatment(1)
No severe complications such as phthisis bulbi, persistent hypotony, or cystoid macular edema(1)
> A repeatable treatment(1)
> A safe treatment potentially allowing for earlier laser interventions
SubCyclo - A new perspective in Glaucoma Treatment
| Yves Lachkar, MD |
Nassima Benhatchi, MD |
| Subcyclo laser procedure results in patients with glaucoma The purpose of this study was to evaluate the efficacy and safety of subliminal cyclophotocoagulation using a 25% duty cycle diode laser (Supra 810, SubCyclo, Quantel Medical). By Nassima Benhatchi, Djawed Bensmail, Yves Lachkar |
READ |
| Subcyclo laser procedure results in patients with glaucoma Transscleral cyclophotocoagulation uses a continuous diode laser and it has been a treatment option in advanced glaucoma cases with suboptimal IOP control. By Romanian Society of Ophthalmology |
READ |
| Significant Improvements for IOP Reduction Seen in SubCyclo As a leading cause of irreversible blindness worldwide, glaucoma affects around 60.5 million people globally. Significant changes in diagnostic criteria, new therapies, and new tools for glaucoma management techniques have benefited individual patients. By Robert Noecker, MD |
READ |
(1) – Efficacy, tolerability, side effects, anatomical effects (UBM) of SubCyclo® subthreshold cyclophotocoagulation. 9-month study (43 eyes / 34 patients) presented at the French Society of Ophthalmology 2017 (SFO). Dr. Yves Lachkar and Dr. Nassima Benhatchi – Glaucoma Institute, Saint Joseph Hospital, Paris (France). Data on file
MORE INFORMATION:
| Introduction to SubCyclo | Treatment Guidelines |
